PROFOUND MEDICAL CORP. Dilutive Effect Of Share Options On Number Of Ordinary Shares
PROFOUND MEDICAL CORP. (PROF) reported Dilutive Effect Of Share Options On Number Of Ordinary Shares of 1.51 million shares for the 12-month period ending 2022-12-31, per its 40-F filed 2023-03-07.
Discontinued › Income Statement › Earnings Per Share
ifrs-full:DilutiveEffectOfShareOptionsOnNumberOfOrdinaryShares · last filed 2023-03-07
| Period end | Dilutive Effect Of Share Options On Number Of Ordinary Shares 12 month |
|---|---|
| 2022-12-31 | 1.51M shares 40-F · filed 2023-03-07 |
| 2021-12-31 | 2.09M shares 40-F · filed 2023-03-07 |
| 2020-12-31 | 1.52M shares 40-F · filed 2022-03-03 |
| 2019-12-31 | 1.11M shares 40-F · filed 2021-03-02 |
| 2018-12-31 | 624.48K shares 40-F · filed 2020-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |